Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
about
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaTherapeutic options in peripheral T cell lymphomaAntibody-drug conjugates--an emerging class of cancer treatmentStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyBelinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective reviewNon-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadGlioblastoma cancer stem cells: Biomarker and therapeutic advancesPrimer on tumor immunology and cancer immunotherapyRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerThe development of immunoconjugates for targeted cancer therapyMarine-Derived Pharmaceuticals - Challenges and OpportunitiesBrentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studiesMechanisms of action of therapeutic antibodies for cancerHighly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic ReviewDiagnostic, prognostic and therapeutic role of CD30 in lymphoma.Novel delivery approaches for cancer therapeutics.Antibody Therapies in Cancer.Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.Bendamustine salvage therapy for T cell neoplasms.Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyRomidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.The heterogeneous landscape of ALK negative ALCL.Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesImmunotherapy in hematologic malignancies: past, present, and future.Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules.Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.Toward a Biology-Driven Treatment Strategy for Peripheral T-cell LymphomaThe role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.Brentuximab vedotin in hodgkin lymphoma and anaplastic large cell lymphoma
P2860
Q24633761-874BB1A6-CA45-4C63-BF81-66013214AB58Q26748857-A77B0299-FB18-4DF6-AE3A-38AFE822382EQ26770312-51A05050-B7F0-4251-99B3-DE693710C523Q26780335-7A882810-168F-4E1A-863A-CEEAB27090D3Q26782270-ECAC4B70-3F21-48E2-AA8C-4AF75671E72AQ26796449-79D177B7-5CA3-4E61-A1EC-3FB1D839D138Q26797513-664746DD-783F-4997-9ABF-C0A5E64C126EQ26859782-96FC4C7C-3CCB-4D4F-AD00-18542C8A684BQ27001126-06CB2612-90EB-42FA-875F-BD9FE7F91E53Q27003258-A3062071-FA71-488E-A069-8E42CAA9AAE8Q27021990-A2FAFD93-5F62-471A-89DF-48FC52C68376Q28075572-70DB69AD-3B1E-491A-B27D-4C030F92456DQ28087540-655F112D-DA06-4D1C-92F9-E0B7932E8D13Q28385366-EBE69958-C920-4617-AE10-418801CCA2B4Q28554530-331085E6-CABF-4032-8DAA-088EE167DE4BQ30240160-09A455DF-7093-4022-B0BD-EC42C3FA7D56Q30368171-98FBDB79-7CF9-409A-AB6F-9021954ECB00Q31104000-62701BF4-91C1-4E56-A27C-5449D18217CEQ33404897-0D7C2780-F26F-412F-A090-9F517918A824Q33407099-DED97168-0E78-4949-8FE9-008D19CA5F51Q33408536-883EF51C-EB93-4915-9560-3F1C577ABA3FQ33409083-6A4E16C9-E533-47D6-BE95-8B8B33F27978Q33410081-54B910D8-F00A-497F-AC1D-979AAE31AA11Q33417191-27A348E8-3FA6-4E26-898F-8A19E696591BQ33418737-F929BC4C-4B38-40D9-A0F9-66492EF1A283Q33423638-E0ACCA5E-C03E-4789-9827-DA4634FCBFF6Q33423816-25DA92BF-757D-4077-B509-CC35E6165CE5Q33428066-CE85793B-6BB0-44A6-8C8F-25395410A8D0Q33431457-25D012EA-A173-4291-A608-C93293FA20FDQ33434137-E24A428E-7C0E-45C9-ABCB-59718B414D88Q33443153-E3836F64-F45E-440A-949D-3D4D4C74FE55Q33567012-E8FB1E3D-7375-4D65-BEF9-691BB8285517Q33592768-0C4672BD-2E25-410D-8427-AF5CC3DE5D4CQ33593865-D7DA99A4-8338-4BA6-B937-7DEE70D87175Q33617362-5494A623-B116-4072-9319-8C71553A6F91Q33648528-B6CDBAB8-948D-4F44-A41D-F0EAA7EE4B08Q33670421-6FD83351-8A9C-4BDD-A7E8-9666211DE620Q33702181-69C38497-15C2-4422-A89E-1FD985F42B04Q33817711-FFF2A150-59EE-4C32-BF02-2BBEE489AA70Q33885565-C7B1C7BA-D0B1-43BC-804C-5A99BC9F12C1
P2860
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Brentuximab vedotin (SGN-35) i ...... : results of a phase II study.
@ast
Brentuximab vedotin (SGN-35) i ...... : results of a phase II study.
@en
type
label
Brentuximab vedotin (SGN-35) i ...... : results of a phase II study.
@ast
Brentuximab vedotin (SGN-35) i ...... : results of a phase II study.
@en
prefLabel
Brentuximab vedotin (SGN-35) i ...... : results of a phase II study.
@ast
Brentuximab vedotin (SGN-35) i ...... : results of a phase II study.
@en
P2093
P50
P356
P1476
Brentuximab vedotin (SGN-35) i ...... : results of a phase II study.
@en
P2093
Andrei Shustov
Barbara Pro
Dana A Kennedy
Eric L Sievers
Jeffrey Matous
Joseph D Rosenblatt
Michelle Fanale
Nancy L Bartlett
Pauline Brice
Radhakrishnan Ramchandren
P304
P356
10.1200/JCO.2011.38.0402
P407
P577
2012-05-21T00:00:00Z